1
Home
Companies

UroGen Pharma

UroGen Pharma
Leadership team

Ms. Elizabeth A. Barrett (Pres, CEO & Director)

Mr. Jason Drew Smith (Gen. Counsel, Chief Compliance Officer & Corp. Sec.)

Dr. Mark P. Schoenberg M.D. (Chief Medical Officer)

Products/ Services
Biopharma, Biotechnology, Clinical Trials, Life Science, Pharmaceutical
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2004
Company Registration
SEC CIK number: 0001668243
Revenue
20M - 100M
Traded as
NASDAQ:URGN
Social Media
URL
https://www.urogen.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
History

UroGen Pharma was founded in 2011 in Jerusalem, Israel, with the mission of improving the life of people with urological conditions. To realize this mission, the Company focuses on leveraging advanced technologies to bring about transformational treatments for its patients.

Mission
Our mission is to develop innovative treatments to improve the lives of patients living with urological cancers and diseases.
Vision
Our vision is to become a leading company in the development of treatments for urological cancers and diseases.
Key Team

Mr. Dong Kim (Chief Financial Officer)

Vincent I. Perrone (Sr. Director of Investor Relations)

Mr. Eric Van Zanten (Sr. Director of Communications)

Dr. Sari Prutchi-Sagiv Ph.D. (Marketing Director)

Dr. Marina Konorty (Exec. VP of R&D and Technical Operations)

Mr. Jeffrey Bova M.B.A. (Chief Commercial Officer)

Mr. James Ottinger R.ph. (Exec. VP of Regulatory Affairs & Quality)

Recognition and Awards
UroGen Pharma has earned numerous awards for its innovative scientific research and contributions to the field of urology, including the Don et al. Innovation Prize from The International Bladder Cancer Network in 2016.
References

https://in.investing.com/equities/urogen-pharma-ltd

https://finance.yahoo.com/quote/URGN/profile?p=URGN

https://www.crunchbase.com/organization/urogen-pharma

https://www.urogen.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

UroGen Pharma
Leadership team

Ms. Elizabeth A. Barrett (Pres, CEO & Director)

Mr. Jason Drew Smith (Gen. Counsel, Chief Compliance Officer & Corp. Sec.)

Dr. Mark P. Schoenberg M.D. (Chief Medical Officer)

Products/ Services
Biopharma, Biotechnology, Clinical Trials, Life Science, Pharmaceutical
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2004
Company Registration
SEC CIK number: 0001668243
Revenue
20M - 100M
Traded as
NASDAQ:URGN
Social Media
URL
https://www.urogen.com